Table 2.
Papers on nestin in liver cancer.
| Authors | Study group | Methodology | Diagnosis | Prognosis | Survival |
|---|---|---|---|---|---|
| Tschaharganeh et al32 | 88 primary HCCs and 47 primary human CCs | Immunostaining with an antibody specifically recognizing the nestin protein | – | Poor | – |
| Yang et al33 | 3 cohorts of pts with HCC: 67, 314, 73 pts | IHC staining | – | Poor | Significant predictor for overall survival (OS) and/or relapse-free survival (RFS) |
| Zhang et al34 | 220 samples of advanced HCC pts | In vitro and in vivo; IHC procedure | – | Significantly associated with metastatic disease | Poor |
| Malvi et al35 | 28 pts with resected mixed primary liver cancer (HCC-CC) | IHC panel | Tool in differential diagnosis | – | – |
| Vasuri et al36 | 39 HCC from 22 patients | Nestin immunostaining | Subclassification of HCC | – | – |
Abbreviations: HCC, hepatocellular carcinoma; IHC, immunohistochemistry; OS, overall survival; RFS, relapse-free survival.